Activity of Cefiderocol and Comparators against Isolates from Cancer Patients
Kenneth V. I. Rolston, Baghat Gerges, Samuel A. Shelburne, Samuel L Aitken, Issam Raad, Randall A. Prince
Abstract
Cefiderocol inhibited 97.5% of 478 Gram-negative isolates from cancer patients at ≤4 mg/liter. It had potent activity against extended-spectrum β-lactamase-positive Enterobacteriaceae , carbapenem-resistant Enterobacteriaceae (CRE), and nonfermenting Gram-negative bacilli, including Pseudomonas aeruginosa , Stenotrophomonas maltophilia , and Acinetobacter species isolates. Amikacin, ceftazidime-avibactam, and meropenem had appreciable activity against non-CRE Enterobacteriaceae .
Topics & Concepts
CancerBiologyMedicineComputational biologyGeneticsNeutropenia and Cancer InfectionsAntibiotics Pharmacokinetics and EfficacyOral health in cancer treatment